Literature DB >> 22089946

Issues regarding 'immortal time' in the analysis of the treatment effects in observational studies.

Jiannong Liu1, Eric D Weinhandl, David T Gilbertson, Allan J Collins, Wendy L St Peter.   

Abstract

In observational studies, treatment is often time dependent. Mishandling the time from the beginning of follow-up to treatment initiation can result in bias known as immortal time bias. Nephrology researchers who conduct observational research must be aware of how immortal time bias can be introduced into analyses. We review immortal time bias issues in time-to-event analyses in the biomedical literature and give examples from the nephrology literature. We also use simulations to quantify the bias in different methods of mishandling immortal time; intuitively explain how bias is introduced when immortal time is mishandled; raise issues regarding unadjusted treatment comparison, patient characteristics comparison, and confounder adjustment; and, using data from DaVita Inc., linked with the Centers for Medicare & Medicaid Services end-stage renal disease database, show that the severity of bias and the issues described can occur in actual data analyses of patients with end-stage renal disease. In the simulation examples, mishandling immortal time led to an underestimated hazard ratio (treatment vs. control), thus an overestimated treatment effect, by as much as 96%, and an overestimated hazard ratio by as much as 138%, depending on the distribution of 'survival' time and the method used. Results from the DaVita data were consistent with the simulation. Careful consideration of methodology is needed in observational analyses with time-dependent treatment.

Entities:  

Mesh:

Year:  2011        PMID: 22089946     DOI: 10.1038/ki.2011.388

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  16 in total

Review 1.  Does Higher Spending Improve Survival Outcomes for Myocardial Infarction? Examining the Cost-Outcomes Relationship Using Time-Varying Covariates.

Authors:  Deborah Cohen; Douglas G Manuel; Peter Tugwell; Claudia Sanmartin; Tim Ramsay
Journal:  Health Serv Res       Date:  2015-02-09       Impact factor: 3.402

2.  Racial Differences in Association of Serum Calcium with Mortality and Incident Cardio- and Cerebrovascular Events.

Authors:  Jun Ling Lu; Miklos Z Molnar; Jennie Z Ma; Lekha K George; Keiichi Sumida; Kamyar Kalantar-Zadeh; Csaba P Kovesdy
Journal:  J Clin Endocrinol Metab       Date:  2016-09-15       Impact factor: 5.958

3.  Pre-transplant alpha-fetoprotein is associated with post-transplant hepatocellular carcinoma recurrence mortality.

Authors:  Nadim Mahmud; Binu John; Tamar H Taddei; David S Goldberg
Journal:  Clin Transplant       Date:  2019-06-25       Impact factor: 2.863

4.  Immortality time and serial myocardial perfusion imaging: Only those who do not die may repeat the exam.

Authors:  Mario Petretta; Marco Salvatore; Alberto Cuocolo
Journal:  J Nucl Cardiol       Date:  2015-05-14       Impact factor: 5.952

5.  Synergistic association of combined glycemic and blood pressure level with risk of complications in US veterans with diabetes.

Authors:  Aidar R Gosmanov; Jun L Lu; Keiichi Sumida; Praveen K Potukuchi; Connie M Rhee; Kamyar Kalantar-Zadeh; Miklos Z Molnar; Csaba P Kovesdy
Journal:  J Hypertens       Date:  2016-05       Impact factor: 4.844

6.  Comparison of Statistical Approaches for Dealing With Immortal Time Bias in Drug Effectiveness Studies.

Authors:  Mohammad Ehsanul Karim; Paul Gustafson; John Petkau; Helen Tremlett
Journal:  Am J Epidemiol       Date:  2016-07-25       Impact factor: 4.897

7.  Association of incident restless legs syndrome with outcomes in a large cohort of US veterans.

Authors:  Miklos Z Molnar; Jun L Lu; Kamyar Kalantar-Zadeh; Csaba P Kovesdy
Journal:  J Sleep Res       Date:  2016-02       Impact factor: 3.981

8.  Association Between Autologous Stem Cell Transplant and Survival Among Californians With Multiple Myeloma.

Authors:  Aaron S Rosenberg; Ann Brunson; Brian A Jonas; Theresa H M Keegan; Ted Wun
Journal:  J Natl Cancer Inst       Date:  2019-01-01       Impact factor: 13.506

9.  Returning to dialysis after kidney allograft loss: conflicting survival benefit beyond transplant-naïve maintenance dialysis patients.

Authors:  Ekamol Tantisattamo; Umberto Maggiore
Journal:  J Nephrol       Date:  2022-01       Impact factor: 3.902

10.  Association between Use of Hydrochlorothiazide and Risk of Keratinocyte Cancers in Kidney Transplant Recipients.

Authors:  Thibault Letellier; Florent Le Borgne; Clarisse Kerleau; Aurélie Gaultier; Jacques Dantal; Simon Ville
Journal:  Clin J Am Soc Nephrol       Date:  2020-11-10       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.